Dr. Jose Baselga, One of the True Giants in Oncology, Dies at 61

The oncology world is mourning the internationally renowned oncologist and cancer researcher Dr. Jose Baselga, who died at the age of 61.
The father of targeted therapies in breast cancer
According to the American Association for Cancer Research, Baselga's research brought significant improvements in survival for patients with breast cancer. Drugs that changed the course of breast cancer, such as trastuzumab (Herceptin), lapatinib (Tykerb), pertuzumab (Perjeta) and everolimus (Afinitor), were evaluated in clinical trials with him in a leading role.
Jean-Charles Soria, director general of Gustave Roussy in Villejuif, France (Europe's most comprehensive cancer center): "One of the true giants in oncology, the brightest mind I knew. He shaped modern oncology and saved many lives" he wrote. He described Baselga as a true friend and mentor and said he was devastated to hear of his death.
Baselga was born in Barcelona, in Spain's Catalonia region. After specializing in oncology, he spent the early years of his medical career in the United States, but returned to Barcelona to lead the oncology service at Vall Hospital d’Hebron (1996-2010). During this time, he founded the Vall d’Hebron Institute of Oncology (VHIO).
A friend, mentor, and also the current director of VHIO, Dr. Josep Tabernero, wrote in memory of Baselga that the cutting-edge research he led put Barcelona and Vall d’Hebron on the international cancer map and made it one of the world's most competitive centers.
Baselga moved to the United States in 2010. He was head of Hematology-Oncology at Massachusetts General Hospital in Boston and later became medical director and physician-in-chief of Memorial Sloan Kettering Cancer Center (MSKCC) in New York City (2012-2018).
However, after Propublica and the New York Times reported on articles Baselga had written in prestigious medical journals such as The Lancet and The New England Journal of Medicine — writing that he had failed to disclose his financial relationships with pharmaceutical companies — he left MSKCC under controversial circumstances (he was alleged to have left with a severance payment worth 3.5 million dollars).
He resigned from MSKCC. He said the omissions were unintentional, but that he took full responsibility and had corrected the information about conflicts of interest in the publications. He added that although he had been inconsistent in disclosing his relationships with these companies, the validity of the research and published studies had not been questioned.
In the last 2 years of his life, he served as executive vice president of oncology research and development at AstraZeneca. The company's CEO, Pascal Soriot, said in a statement: "An outstanding scientific leader, Jose leaves a lasting legacy in the scientific community and here at AstraZeneca."
Soriot: “He set our oncology R&D function on a remarkable trajectory, and with Enhertu (trastuzumab deruxtecan) and datopotamab deruxtecan, he supported the clinical development collaboration with Daiichi-Sankyo” he said.
Baselga served as president of the American Association for Cancer Research (AACR) from 2015 to 2016.
The AACR stated: “Dr. Baselga's death is a great loss for cancer research” it said.
Margaret Foti, CEO of the AACR: “He played a pioneering role in the clinical trials of several drugs that form the foundation of cancer treatment. He was a caring oncologist and a mentor who supported an entire generation of physicians and scientists. He will be greatly missed around the world for his major contribution to cancer science and improved care for cancer patients“ she says.
The shocking news of his death
The news of Baselga's death shocked many of his colleagues and friends.
The Spanish newspaper La Vanguardia identified a rapidly progressing and invariably fatal degenerative neurological disorder, Creutzfeldt-Jakob disease (CJD), as the cause of death.
The newspaper: “As soon as he learned of the diagnosis, he decided to spend the final weeks of his life in Catalonia. He died at his home in La Cerdanya with his family by his side” it wrote. He is survived by his wife and four children.
His daughter Clara Baselga-Garriga, a medical student, set up a GoFundMend page for CJD research. “We are asking for donations for those at the forefront of cutting-edge neurodegenerative research. We hope that one day no family will have to experience this pain.”
“Science is battling an enigma with CJD, and unfortunately there is no treatment that works” she wrote. She noted that patients live between 3 weeks and 6 months from the onset of symptoms.
Baselga-Garriga also stated that her father died of sporadic CJD, a form different from genetic CJD or iatrogenic CJD (transmitted from infected instruments during surgery or contaminated meat — mad cow disease). She added that CJD affects one person per million each year.
Sources
Was this article helpful?
Your feedback helps us improve our content.





Reader comments
Share your comment
Your name and comment are published only after administrator approval. Your email address is never shown to visitors.
Be the first to comment.